Trial Profile

Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; E 6201 (Primary)
Indications Brain metastases; Malignant melanoma
Focus Adverse reactions

Most Recent Events

05 Feb 2025 Status changed from recruiting to active, no longer recruiting.
16 Sep 2024 Planned number of patients changed from 18 to 25.
16 Sep 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com